

Please fill out your details on the form provided and email to GSK Vaccines Department: elizabeth.x.lonie@gsk.com or post to GlaxoSmithKline, PO Box 18095 Melbourne 8003 **PLEASE PRINT IN BLOCK LETTERS**

Title: _____ Name: _____ Occupation: _____

Organisation: _____

Address: _____

Phone: _____ Email: _____

☐ I would like to speak with a GSK Representative

HEALTHCARE PROFESSIONAL RESOURCES

SHINGRIX (FOR USE WITH PATIENTS) WHAT YOU NEED TO KNOW 10 PAGE A4 TEAR OFF PAD NP-AU-SGX-LBND-230003 QTY _____	SHINGRIX (FOR USE WITH PATIENTS) NIP WHAT YOU NEED TO KNOW 20 PAGE A4 TEAR OFF PAD NP-AU-SGX-LBND-230004 QTY _____	SHINGRIX (FOR HCPs) PHARMACY DISCUSSION GUIDE PM-AU-SGX-LBND-230049 QTY _____	SHINGRIX (FOR HCPs) SHINGRIX Patient Eligibility Screener PM-AU-SGX-LBND-230043 QTY _____	GSK VACCINES VACCINES MAGNETIC CHART PM-AU-TVX-PSTR-230001 QTY _____
SHINGRIX (FOR HCPs) SHINGRIX NIP vaccination coverage: What progress has been made? PM-AU-SGX-LBND-250001 QTY _____	SHINGRIX (FOR HCPs) SHINGRIX HCP DISCUSSION GUIDE PM-AU-SGX-LBND-240007 QTY _____	SHINGRIX (FOR HCPs) SHINGRIX NIP DISCUSSION GUIDE PM-AU-SGX-LBND-230043 QTY _____	SHINGRIX (FOR HCPs) SHINGRIX Presentation Folder PM-AU-SGX-HO-230001 QTY _____	SHINGRIX (FOR HCPs) RECONSTITUTION GUIDE PM-AU-SGX-LBND-230018 QTY _____

GSK Representative Name: _____

Phone: _____ Email: _____

DISEASE AWARENESS MATERIAL

<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>SHINGLES DISEASE AWARENESS POSTER A</p> <p>NP-AU-HZU-PSTR-230001</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>SHINGLES DISEASE AWARENESS POSTER B</p> <p>NP-AU-HZU-PSTR-230001</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>SHINGLES DISEASE AWARENESS POSTER C</p> <p>NP-AU-HZU-PSTR-230001</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>SHINGLES IS SLEEPING FLYER</p> <p>NP-AU-HZU-PSTR-230002</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>SHINGLES IS SLEEPING POSTER</p> <p>NP-AU-HZU-PSTR-230002</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>GREEK SHINGLES PATIENT BROCHURE</p> <p>NP-AU-HZU-BROC-230001</p> <p>QTY _____</p>
<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>CHINESE SIMPLIFIED SHINGLES PATIENT BROCHURE</p> <p>NP-AU-HZU-BROC-230001</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>CHINESE TRADITIONAL SHINGLES PATIENT BROCHURE</p> <p>NP-AU-HZU-BROC-230001</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>KNOW SHINGLES POSTER A</p> <p>NP-AU-HZU-PSTR-240001</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>KNOW SHINGLES POSTER B</p> <p>NP-AU-HZU-PSTR-240001</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>KNOW SHINGLES A5 BOOKLET</p> <p>NP-AU-HZU-PSTR-240001</p> <p>QTY _____</p>	<p>SHINGLES EDUCATION (FOR PATIENTS)</p> <p>KNOW SHINGLES TEAR OFF PAD</p> <p>NP-AU-HZU-PSTR-240001</p> <p>QTY _____</p>

How you can stay informed with GSK

GSK believes it is important to provide timely and useful information related to our medicines and vaccines to add value to your practice. If you would like to embark on a digital journey with us, we will need your email consent.

Examples of what you can expect to receive:

- Scientific updates
- Webinars and events (e.g. webinar invitations and post symposium highlights)
- Information about our products
- Disease awareness materials (e.g. patient videos, brochures)

To access the above please use the QR code or link: www.stayinformed.gskpro.com.au



Please review full SHINGRIX Product Information before prescribing.
Product Information can be accessed at www.gsk.com.au/shingrix

PBS Information: SHINGRIX is listed on the National Immunisation Program (NIP) for Aboriginal and Torres Strait Islander adults aged ≥50 years, for all individuals aged ≥65 years and for adults aged ≥18 years with some immunocompromising medical risk conditions. Refer to NIP schedule or your State or Territory Health department.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reportingproblems

We, GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 collect, use and disclose personal information about you so we can perform our business activities and functions. We collect your personal information in order to administer medical education programs or other similar programs organised by us, send you material on and contact you regarding our activities and products. If we do not collect your personal information we may be unable to provide you with all of our services, for example information regarding our programs, events, services or products which may be of benefit to you. We will only disclose your personal information as necessary to third parties that we use in the ordinary operation of our business, such as for conference organising, marketing, data processing and associated printing and mailing. We will not disclose your personal information overseas. Our privacy policy can be found at <http://www.gsk.com.au/privacy.aspx> and contains information about how you may access and correct personal information held by us and how you can complain about a breach of privacy and how we will deal with such a complaint. If you require, you may access the information we hold about you by writing to the Privacy Officer, GlaxoSmithKline Australia Pty Ltd. PO Box 18095, Melbourne, Victoria, 8003.

For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. GlaxoSmithKline Australia Pty Ltd. Melbourne, VIC. Trade marks are owned by or licensed to the GSK group of companies ©2025 GSK group of companies or its licensor PM-AU-AVX-BROC-210001. Date of approval: April 2025.